Overview

Study of LY2835219 for Mantle Cell Lymphoma

Status:
Active, not recruiting
Trial end date:
2022-04-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company